

## Prevention & Treatment of Hepatitis and Chronic Liver Disease

**Raleigh-Durham, NC – March 23, 2024**

|                            |  |   |
|----------------------------|--|---|
| <b>Conference Location</b> | <b>Sheraton Imperial Hotel</b><br>4700 Emperor Boulevard<br>Durham, NC 27703 | <b>Phone: (919) 941-5050</b><br><br><a href="http://www.sheratonrtp.com">http://www.sheratonrtp.com</a> |
|----------------------------|--|---|

|                                  |   |
|----------------------------------|---|
| <b>Parking at the Conference</b> | Complimentary parking has been arranged for all seminar participants. |
|----------------------------------|---|

|                           |  |
|---------------------------|--|
| <b>Driving Directions</b> | <p><b>From East or West</b></p> <ul style="list-style-type: none"> <li>• Follow Interstate 40 to Exit 282 (Page Road).</li> <li>• Follow the exit on Page Road and the hotel will be at the top of the hill on the left</li> </ul> <p><b>From the South:</b> Follow Interstate 95 North to Interstate 40 West.</p> <ul style="list-style-type: none"> <li>• Travel on I-40 west to Exit 282 (Page Road).</li> <li>• Turn right onto Page Road and then turn left at the first light.</li> <li>• The hotel is approximately one quarter of a mile ahead on the left.</li> </ul> |
|---------------------------|--|

|  |   |
|--|---|
| <b>Seminar Agenda and Syllabus Information</b> | Registration begins at <b>7:30 a.m.</b> outside the Auditorium.<br><br><b>The Hepatitis and Chronic Liver Disease seminar is a paperless program. The course syllabus and related materials will be made available on a digital app</b> that can be accessed by a smart phone, tablet or personal computer. Instructions to download the <i>App</i> will be provided. Wi-Fi will be available without charge. |
|--|---|

|                               |  |
|-------------------------------|--|
| <b>Pre-Program Activities</b> | <b>Pre-Lecture 1 – Viral Hepatitis</b> –A summary for discovery and natural history of HCV 60 min<br><b>Pre-Lecture 2 - End Stage Liver Disease:</b> An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min  |
| <b>7:30 am</b>                | <i>Registration and View Exhibits</i>  |
| <b>8:00 am</b>                | <b>Opening Comments and Pre-Test</b>   |
| <b>8:20 am</b>                | <b>Advances in the Screening and Treatment of HCV</b> <ul style="list-style-type: none"> <li>• Updates on diagnostic approaches</li> <li>• Caring for At-risk populations – homeless, PWID, the incarcerated</li> <li>• Novel FDA Approved Direct Acting Anti-virals</li> <li>• Clinical Cases and Discussion</li> </ul>   |
| <b>9:10 am</b>                | <b>Hepatitis B: Epidemiology, History, Testing and Treatment</b> <ul style="list-style-type: none"> <li>• The epidemiology of the Hepatitis B infection</li> <li>• Efficacies and opportunities in HBV testing and vaccination</li> <li>• The efficacy of HBV Vaccination and Anti-viral therapies of HBV</li> <li>• HBV Re-activation and the Latest studies from EASL and AASLD</li> </ul> |
| <b>9:40 am</b>                | <b>Delta Hepatitis and Hepatitis E Update</b> <ul style="list-style-type: none"> <li>• Global and US perspective on the growth of Delta Hepatitis</li> <li>• Lonafarnib and Bulevirtide of HDV: Benefits and potential hazards</li> <li>• Testing and surveillance approaches</li> <li>• Real world outcome studies on HDV and HEV</li> </ul>  |
| <b>10:15 am</b>               | <i>Break and View exhibits</i>   |
| <b>10:30 am</b>               | <b>End Stage Liver Disease: Recap and Clinical Cases</b> <ul style="list-style-type: none"> <li>• A review of Pre-course lecture on end-stage liver disease</li> <li>• Complications of cirrhosis</li> </ul>   |

|                                |  |
|--------------------------------|--|
|                                | <ul style="list-style-type: none"> <li>• Liver transplant in the era of DAA's</li> <li>• Clinical cases to illustrate HE, HRS and/or Thrombocytopenia</li> </ul>   |
| <b>11:05 am</b>                | <b>Hepatocellular Carcinoma(HCC) - Screening and Disease Progression</b> <ul style="list-style-type: none"> <li>• Screening diagnostic serum assays and imaging tests</li> <li>• Treatment and management options: Ablation, TACE and Surgery</li> <li>• New studies showing cost effectiveness of surveillance post SVR</li> <li>• PRIUS Study (MRI vs US) Abbreviated MRI</li> <li>• 2023 AASLD screening guidance for liver cancer and comments on biopsy for HCC</li> </ul>                        |
| <b>11:40 am</b>                | <b>Hepatocellular Carcinoma: A case-based approach to New Systemic Treatment Options</b> <ul style="list-style-type: none"> <li>• Promising 1<sup>st</sup> and 2<sup>nd</sup> line therapies for liver cancer</li> <li>• New data on the benefit of downstaging</li> <li>• C chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC</li> <li>• Checkpoint inhibitors and VEGE inhibitors</li> </ul>   |
| <b>12:20 pm</b>                | <b><i>Luncheon and Product Information Session</i></b>   |
| <b>12:55 pm</b>                | <b><i>Dessert and View Exhibits</i></b>  |
| <b>1:05 pm</b>                 | <b>Cholestatic Liver Disease: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis</b> <ul style="list-style-type: none"> <li>• Epidemiology of PSC and Ursodiol and Antibiotic Treatments</li> <li>• Causes and Markers of PBC</li> <li>• Coping with the clinical features of PBC</li> <li>• Ursodeoxycholic Acid (UDCA) and Obeticholic Acid</li> <li>• Highlights of the ELATIVE study on elafibranor and the ENHANCE study on seladelpar</li> </ul>                                     |
| <b>1:55 pm</b>                 | <b>Alcohol Associated Liver Disease</b> <ul style="list-style-type: none"> <li>• The growing prevalence of alcohol over-consumption and its impact on liver health</li> <li>• Alcohol consumption and malnutrition</li> <li>• Warning signs and intervention in alcohol-associated hepatitis</li> <li>• Promising therapeutic agents for AAH</li> </ul>  |
| <b>2:30 pm</b>                 | <ul style="list-style-type: none"> <li>• <b><i>Break &amp; View Exhibits</i></b></li> </ul>  |
| <b>2:45 pm</b>                 | <b>Steatotic Liver Disease: The new healthcare epidemic</b> <ul style="list-style-type: none"> <li>• New naming conventions for fatty liver disease: MASLD and MASH– what and why?</li> <li>• Epidemiology, Demographics and Diagnosis</li> <li>• Scoring, Staging and Management of Metabolic Liver Disease</li> <li>• The ‘unhealthy’ rise in MASLD in the US population and What can be done<br/>Treatment options for thrombocytopenia; including alternatives to platelet transfusion.</li> </ul> |
| <b>3:20 pm</b>                 | <b>MASH Treatments in Practice and in Development</b> <ul style="list-style-type: none"> <li>• Current therapies for NASH including Updates from AASLD and EASL</li> <li>• Lifestyle changes as a therapy</li> <li>• Drugs in clinical development for NASH – Semaglutide and Resmieron</li> <li>• MASH Diagnosis and Treatment case</li> </ul>  |
| <b>4:00 pm</b>                 | <b>Closing Comments, Post-test and Wrap-Up</b><br>Program adjourns at 4:15 pm  |
| <b>Post-program activities</b> | <b>Lecture 3 - Fluid Management, Ascites and Hepatorenal Syndrome</b> 30 minutes<br><b>Lecture 4 - Overcoming barriers to liver health in special populations</b> - 30 minutes.<br><b>Lecture 5 – AASLD Update – Highlights of the 2023 Liver Meeting</b> – 30 minutes   |

**Attendance Policies**

**Attendee Cancellation, Substitution, Refund**

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

---

**Recording and Photography**

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

**Guest Attendance**

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues, and others.) are not permitted in the seminar areas.

**Conference Modification or Cancellation**

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course's schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

---

**Physicians (MD/DO)** - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)**<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**CME Information**

**Nurses** - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-24-1383. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

**Nurse Practitioners and Physician Assistants** - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)<sup>™</sup> organizations accredited by ACCME.

---

**A. SIDNEY BARRITT, IV, MD, MSCR, FAGA**

Sidney Barritt received his medical degree from University of Virginia School of Medicine in Charlottesville after graduating with a BA in History from the University of Virginia. Later, Dr Barritt continued his education studying Epidemiology and receiving a Master's of Science in Clinical Research degree at the Gillings School of Global Public Health, University of North Carolina-Chapel Hill.

Dr. Barritt is certified in Internal Medicine, Gastroenterology and Transplant Hepatology. Clinically, Dr. Barritt is interested in non-alcoholic fatty liver disease and liver transplant outcomes research. He participates in clinical and diagnostic trials and collaborates with research partners in the UNC school of Pharmacy and School of Public Health.

**Your Seminar Faculty****LINDSAY KING, MD, MPH**

Dr. Lindsay King is a hepatologist with a particular interest in liver transplantation as well as in the care of patients with autoimmune hepatitis and primary biliary cholangitis. She has recently presented at both the Autoimmune Hepatitis Associations' national meeting for patient support and education as well as the PBC'ers national conference. She is the Medical Director for Liver Transplantation at Duke University and cares for patients both before and after transplantation at a high-volume transplant center.

Dr. King completed her undergraduate education at Wake Forest University, followed by medical school at the University of Virginia. She went on to complete her internal medicine internship and residency at Brigham and Women's Hospital where she served as a chief medical resident.

**ELIZABETH GOACHER, PA-C**

Elizabeth K Goacher is a Physician Assistant Specialist in Durham, North Carolina. She graduated with honors from Duke University School of Medicine in 1998. Having more than 19 years of diverse experiences, especially in treating patients with liver and other GI diseases.

She is affiliated with many hospitals including Duke University Hospital, Duke Health Raleigh Hospital, Duke Regional Hospital, and cooperates with other doctors and specialists in medical group Private Diagnostic Clinic.